Search Videos and More

Showing 1 - 12 of 643 results

Previous| 1 | 2 | 3 ...54 |Next


Jorge J. Castillo, MD discusses results from a multicenter phase 2 Study Video

Jorge J. Castillo, MD discusses results from a multicenter phase 2 Study

High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenstrom macroglobulinemia
Andrew A. Lane, MD, PhD discuss results from a phase 2 Study Video

Andrew A. Lane, MD, PhD discuss results from a phase 2 Study

Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendtritic cell neoplasm (BPDCN)
Reid W. Merryman, MD discusses results of a multicenter phase II trial Video

Reid W. Merryman, MD discusses results of a multicenter phase II trial

Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma
Omar Nadeem, MD discusses results of the Phase II d-PRISM study Video

Omar Nadeem, MD discusses results of the Phase II d-PRISM study

Daratumumab in high-rish MGUS and low-risk smoldering myeloma
Mahasweta Gooptu, MD discusses results from the NMDP-sponsored access expansion Study Video

Mahasweta Gooptu, MD discusses results from the NMDP-sponsored access expansion Study

Phase 2 Study of post transplant cyclophosphamide-based graft versus host disease prophlaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning
Jacqueline Garcia, MD discussed results from the Phase # VERONA study Video

Jacqueline Garcia, MD discussed results from the Phase # VERONA study

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacititine (Pbo+Aza) in patients with treatment-naive, intermediate and higher-risk Myelodysplastic Syndromes (HR-MDS)
Shayna Sarosiek, MD discusses WM-NET 1 trial Video

Shayna Sarosiek, MD discusses WM-NET 1 trial

Deep responses following treatment with Ioncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those with high risk, TP53-altered Waldenstrom macroglobulinemia.
Austin Kim, MD discusses phase I/II study Video

Austin Kim, MD discusses phase I/II study

Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)
Jennifer Brown, MD, PhD discusses results form the ALPINE trial Video

Jennifer Brown, MD, PhD discusses results form the ALPINE trial

Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Marlise Luskin, MD, MSCE discusses results of a phase 1 trial Video

Marlise Luskin, MD, MSCE discusses results of a phase 1 trial

Venetoclax plus inotuzumab ozogramicin for relapsed and refractory ALL: Results of a phase 1 trial
Maria Capilla Guerra, MD discusses rapid diagnosis of acute leukemia with integrated epigentic and genetic profiling Video

Maria Capilla Guerra, MD discusses rapid diagnosis of acute leukemia with integrated epigentic and genetic profiling

Tip Sheet: Medication-Related Osteonecrosis of the Jaw Document

Tip Sheet: Medication-Related Osteonecrosis of the Jaw

The Breast Oncology Center developed this reference for providers caring for patients with medication-related osteonecrosis of the jaw in November 2025.

Showing 1 - 12 of 643 results

Previous| 1 | 2 | 3 ...54 |Next